特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 抢好礼 倒计时 ！ 大咖齐聚论道： SCIEX 全球副总裁蔡俊松、中国科学院上海有机化学研究所研究员郭寅 龙等众多业内权威专家齐聚一堂，分享驱动组学研究的非凡发现，探讨高分辨质谱与 AI 技术 赋能药物研发的前沿趋势。 SCIEX年中新品发布会！ZenoTOF 8600高分辨质谱"极速超敏" 黑科技 首秀，一场科技与 惊喜交织的盛会等你加入！ 还有好礼赠送 ： 识别二维码或点击"阅读原文" 立即报名 *报名准时参会，奖品随机抽取 直播亮点抢先看 灵敏度逆天提升： ZenoTOF 8600 系统灵敏度较 ZenoTOF 7600+ 直接飙升 10 倍， 微量物质也能精准捕捉，科研检测从此有了"超级放大镜"。 礼品清单 性能全面升级： 800Hz 扫描速度轻松突破，数据获取如闪电般迅速；系统耐用性拉满， 稳定运行无压力，为你的科研之路保驾护航。 | 版 权 ： 本 文 部 分 素 材 源 自 网 络 ， 版 权 归 原 作 者 所 有 ， 观 点 代 表 作 者 本 人 ， 不 代 表 本 号 ...

近日，华熙生物公众号发布《关于透明质酸和重组胶原蛋白的传言与真相》。当中谈到，资本市场概念 切换带来的关于透明质酸和重组胶原蛋白的误导性认知，已经远远偏离了科学和产业发展的基本面。如 果不加以纠正，不但会影响到华熙生物等一大批企业的经营环境，也会给以重组胶原蛋白为经营概念的 企业带来资源错配和风险，因为任何从业者都不可能绕开生物学的基本规律和产业的基本规律走得太 远。 近几年基于基因工程表达的重组胶原蛋白获得了快速发展，华熙生物也在从事相关的研究和产业转化， 华熙生物的重组胶原蛋白原料已初步经过市场验证，正持续供应给其他行业企业。但有几个基本的事实 一直在提醒我们把握好"先行先试"和"全球领先"之间的表述差异：首先，"重组的"胶原蛋白只是胶原蛋 白研究和产业转化当中很小的一个分支，整个蛋白质组学研究，包括胶原蛋白研究和转化的制高点依然 掌握在生命科学研究机构和医药企业手中，并不掌握在医美或化妆品公司，资本市场不能不顾这些基本 事实去引导对"全球领先"的错误预期。 其次，以基于重组胶原蛋白的医美三类械证书为例，国际上还没有相关的准入批复，这当然说明我们在 先行探索，另一方面也说明我们需要更长的实践观察周期。 而 ...

编辑丨王多鱼 排版丨水成文 在 癌症 领域， 男性 始终面临一个 " 不公平 " 的现实：相较于女性， 男性不仅更容易患癌，而且更容易死于癌症 。这种性别差异广泛存在于肝癌、膀胱癌、食 管癌、头颈癌等非生殖系统肿瘤中。 该研究首次从 肿瘤细胞 与 免疫细胞 双谱系角度，系统揭示了 Y 染色体缺失 （LOY） 如何协同影响肿瘤进程与患者生存结局。 该研究指向一个被忽视已久的关键角色 —— Y 染色体 ，提出了男性体内一种常见的遗传现象—— Y 染色体缺失 （ Loss of Y chromosome，LOY ） ，可能是 推动癌症进展、削弱免疫反应、缩短患者生存期的根源之一 。 更重要的是，这种 " 缺失 " 并非仅发生于肿瘤细胞本身，该研究发现， 肿瘤细胞中的 Y 染色体缺失会传播扩散到免疫细胞 T 细胞中，导致 T 细胞失去抗癌能力 。这意味着， 癌症对于男性而言，不仅是一次 " 突变 " 的恶性起点，更是一场由内而外的系统性崩塌 。 值得一提的是，这项研究还登上了 Nature 官网头条。 然而，究竟是什么在背后悄然操控这一生物学不平等现象？长期以来，答案并不清晰 。 2025 年 6 月 4 日， 陈兴 ...

AI 助力多组学与机器学习联合分析 课题特色 ： 1. 零基础 无压力，R语言编程从入门到实战，快速打造你的生信分析基本功； 2. AI赋能 +CNS文献精读，带你高效拆解多组学科研的 经典范式与创新思路 ； 3. 全面覆盖 代谢组、蛋白组、微生物组（宏基因组和16s） 、 转录组 等热门方向，紧跟科研前沿； 机器学习分析多组学课程内容 第一节课 AI+多组学CNS论文思路解读 1.基于Deepseek高效阅读多组学的CNS生信文章 2.AI整理代谢组、蛋白组、宏基因组等多组学数据分析流程 3.Deepseek从多篇生信文献中快速总结提炼多组学数据分析方法 4.Deepseek评价多组学生信文章思路的创新性和数据分析可行性 第二节课 Deepseek辅助多组学生信课题设计 1.Deepseek辅助代谢组、蛋白组、宏基因组联合分析策略 2.AI指导代谢组、蛋白组、宏基因组、转录组交叉验证的思路 3.Deepseek汇总生信论文模板设计的层次和逻辑要点 4.Deeoseek辅助生信多组学数据研究热点挖掘 5.Deeoseek构建多个公共数据库联合验证有效策略 第三节：编程基础学习--R语言 1.R和Rstudio ...

Group 1 - In May 2025, the number of newly registered private equity and venture capital fund managers in China dropped to 2, a decrease of 83.3% compared to April and a 60% decline year-on-year [1] - A total of 339 new private equity and venture capital funds were registered, marking a year-on-year increase of 55.5% but a month-on-month decrease of 18.7% [1] - The domestic primary equity investment market recorded 428 financing events, representing a year-on-year decrease of 13.6% and a month-on-month decrease of 18.0% [1] Group 2 - Shenzhen Innovation Investment Group (Deep Venture) has registered a new fund, the Shenzhen Hongtu Seed Fund, with a total capital contribution of 300 million yuan, focusing on advanced technology sectors [2] - The Shenzhen Semiconductor and Integrated Circuit Industry Investment Fund aims for a total scale of 5 billion yuan, with 3.6 billion yuan already contributed by various local government funds [3] Group 3 - Deep Venture disclosed 10 equity investment events in the reporting period, a fivefold increase compared to May 2024 and a 66.7% increase from April [3] - In the first five months of 2025, Deep Venture made 43 investments, which is 58.1% of its total investments in 2024 [3] Group 4 - 60% of Deep Venture's projects in May were in the angel and A-round early stages, with a focus on advanced manufacturing, particularly in integrated circuits and aerospace [6] - The company invested in "Sailu Medical," which completed an A+ round of financing, with funds aimed at expanding its sequencing platform and global market outreach [11][12]

Summary of Bruker (BRKR) 2025 Conference Call Company Overview - **Company**: Bruker Corporation (BRKR) - **Event**: 2025 Conference Call held on June 04, 2025 Key Industry Insights - **Industry**: Mass Spectrometry and Proteomics - **Market Trends**: The mass spectrometry market is experiencing significant innovation, particularly in proteomics and metabolomics, with a focus on high sensitivity and throughput solutions [3][10][12] Core Product Innovations 1. **TIMS Ultra and AIP**: - New product launched to enhance MSMS sensitivity and bandwidth, allowing for more peptides and proteins to be analyzed [5][7] - Significant advancements in single-cell proteomics, enabling analysis of smaller cells than previously possible [8] 2. **TIMS Metabo Instrument**: - Aimed at the high-resolution accurate mass market for small molecules, targeting applications in PFAS research, toxicology, and metabolomics [11][12] - Expected to double the market opportunity for Bruker, potentially reaching a $200 million market share [15] 3. **TIMS Omni**: - A revolutionary mass spectrometer combining TIMS technology with Omni Trap, enabling top-down proteomics and functional proteomics [17][18] - Positioned to create a new category in mass spectrometry with no direct competition [19] Financial Outlook - **Revenue Guidance**: Anticipated moderate growth in 2026, with expectations of organic growth between 6% to 8% [32] - **Cost Management**: Bruker is implementing cost-cutting measures, including reducing operational costs in European sites and optimizing R&D spending [33][35] Market Dynamics - **Academic Market**: Anticipated decline in academic spending by 20-25% due to budget constraints, impacting overall revenue [22][30] - **Defense and Homeland Security**: Notable growth in the detection business for radiological and chemical threats, with potential revenue increases of $20 million next year [38][39] Emerging Markets and Opportunities - **Semiconductor and AI**: Strong demand in metrology for high-performance computing and AI applications, expected to grow from 8% to potentially 12% of total revenue [45][46] - **China Market**: Potential for stimulus-driven growth in high-end research tools, although timing remains uncertain [51][52] Strategic Developments - **Cell Analysis and Diagnostics**: Launch of a new benchtop product aimed at broadening market access for antibody discovery and cell line selection [54][55] - **Spatial Biology**: Continued investment in spatial biology technologies, enhancing capabilities in multi-omics and improving throughput and detection efficiency [61][62] Conclusion - Bruker is positioned for growth through innovative product offerings in mass spectrometry and proteomics, despite facing challenges in academic funding and market uncertainties. The company is strategically focusing on high-growth areas such as biopharma, diagnostics, and advanced manufacturing technologies.

Summary of Biotechni Conference Call Industry Overview - The life science tools industry is experiencing significant volatility due to macroeconomic factors and uncertainties, particularly in the U.S. and China [1][3] - The company has observed a recovery in the life science tools space, particularly in the pharmaceutical sector, which has shown double-digit growth across various geographies [3][4] Company Performance - The company reported double-digit growth in the pharmaceutical segment, which is widespread across its portfolio [4] - Academic revenue, which constitutes about 12% of total revenue, has been stable despite discussions of NIH budget cuts [5][6] - The worst-case scenario of a 40% cut in NIH funding would only result in a negative 1% impact on the company's projected growth rate over five years [6][7] Market Dynamics - Smaller biotech firms have been conservative in spending due to external market uncertainties, impacting their growth [9][10] - The pharmaceutical sector has seen a slight deceleration in growth rates from double digits to mid-single digits due to tariff discussions and pricing uncertainties [11][12] Academic Market Insights - Academic sales have remained stable despite concerns over funding cuts, attributed to the psychological impact on purchasing behavior [15][17] - Daily sales in the academic sector have shown stability over the past three months, indicating a return to normalcy [17] Instrumentation and Product Lines - The instrumentation segment, which accounts for about 20% of revenue, has seen growth driven by the biologics platform and specific products like the Maurice instrument [18][19] - The company is well-positioned in the bioprocessing market, with opportunities in biosimilars and other emerging markets [19][20] Tariff Impact and Mitigation Strategies - The company has low exposure to tariffs, with most of its reagents exempt from tariff increases [22][23] - Manufacturing strategies include moving production to Canada and stocking inventories in Europe and Asia to mitigate future tariff impacts [25][26] China Market Dynamics - China represents 88% of the company's revenues, and there are signs of a subtle shift towards optimism in customer demand [27][28] - The company is targeting the replacement of older instruments with newer technology, which is expected to drive growth [30][31] - Despite competition, the company maintains a strong position based on quality and consistency, which are prioritized by customers [34] Long-term Growth Outlook - The company remains bullish on long-term growth in China, driven by an aging population and ongoing scientific innovation [35][36] - The life science tools market is expected to grow significantly, with the company well-positioned to capitalize on these trends [37] Liquid Biopsy Segment - The liquid biopsy business is focused on scaling sustainably, with growth rates exceeding 20% [39] - The company is integrating exosome technology into its kit business, targeting multiple tests for disease monitoring [40][41] Spatial Market Position - The company is differentiating itself in the mid-plex spatial market by offering integrated solutions that combine molecular and antibody reagents [46][48] - The competitive landscape includes key players like Akoya and Molteni, but the company has a high win rate against these competitors [53] Margin Performance - The company achieved nearly 200 basis points of margin improvement year-over-year, although a contraction of approximately 150 basis points is expected in the near term due to tariffs and lower growth rates [54][55] - The long-term target is to achieve operating margins above 35%, supported by organic growth and effective cost management [55]

以下文章来源于SCIEX ，作者SCIEX SCIEX . SCIEX 中国，让质谱改变每个人的生活！ 美国东部时间2025年6月2日上午7时 (承接SCIEX高端四极杆7500+系统) ： 在ASMS 2025年会上，全球生命科学分析技术创新者、丹纳赫集团（纽约证券交易所代码：DHR）旗下运 营公司SCIEX正式推出ZenoTOF 8600系统，为高分辨质谱产品树立全新标杆。该系统在定性和定量的能力 均有出色表现，其不仅提升了对复杂结构的解析能力，还能使科学家能够在短时间内从复杂样本中精准定 量数千种物质。 ZenoTOF 8600系统将高灵敏度性能与SCIEX数十年的三重四极杆创新经验相承接，其 核心突破技术包 括： OptiFlow Pro离子源、DJet离子导入 和双频QJet离子导向器： 显著提升离子生成与传输效率，结合ZenoTrap离子阱技术，灵敏度较前代产品提升10倍。 Mass Guard技术 有效防止系统污染，延长仪器稳定运行时间。 新型光学检测器： 支持更高离子电流下的高效运行。 ZT Scan DIA 2.0模式： 对SCIEX领先的DIA数据非依赖性采集技术进一步升级，赋能更广质量范 ...

导读： 赛默飞世尔在ASMS2025推出Orbitrap Astral Zoom和OrbitrapExcedion Pro质谱仪，助力生物过程解密与疾病研究突破。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 美国当地时间2025年6月2日，赛默飞世尔科技（NYSE: TMO）于第73届美国质谱年会（ASMS）重磅推出两款革新性质谱仪： Thermo Scientific™ Orbitrap™ As tral™ Zoom 质谱系统和Thermo Scientific™ Orbitrap™ Excedion™ Pro 质 谱 系 统 。 这 两 款仪 器 以 卓 越 的分析性能与速度，致力于解密复杂生物过程，推动阿尔茨海默症、癌症等重大疾病研究的突破，为精准医学与生物制药开发提供全新引擎。 Orbit r ap Ast r a l Zo om 创新技术亮点： 超高速扫描：35%的速度提升加速海量数据采集 极致通量：40%的效率跃升支持大规模样本筛查 智能多重检测：50%的多重能力扩展实现单次实验多维分析 应用拓展： 深度蛋白质组学分析、痕量 ...

导读： ASMS2025会议期间，布鲁克在会上发布timsOmni™、timsMetabo™质谱仪及proteoElute™纳流液相色谱系统等新品，引发广泛关注。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 仪器信息网讯 2 0 2 5年6月1日，第7 3届美国质谱学会年会（ASMS 2 0 2 5）在美国马里兰州巴尔的摩会议中心盛大启幕。本次盛会将持续至6月5 日，预计将吸引全球超过6 5 0 0名顶尖科学家、企业代表及行业专家齐聚一堂。会议期间，将有超过3 0 0 0篇论文通过海报和演讲形式，展示质谱 及相关领域的前沿研究成果。会议期间，布鲁克发布timsOmn i™、timsMe t a b o™质谱仪及p r o t e oEl u t e™纳流液相色谱系统等新品，引发广泛 关注。 布鲁克（纳斯达克股票代码：BRKR）在ASMS2 0 2 5年度会议上正式发布基于timsTOF质谱仪开发的全新革命性质谱系统 timsOmni™ ，为科 学研究、药物研发、临床研究及生物制剂高级质控等多个领域提供深度的完整生物大分子结构解析能力，可 ...